Global Proteasome Inhibitors Market 2024-2028

The proteasome inhibitors market is forecasted to grow by USD 2.91 bn during 2023-2028, accelerating at a CAGR of 7.48% during the forecast period. The report on the proteasome inhibitoars market provides a holistic analysis, market size, and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by a huge unmet need for certain cancer therapeutics, strong adoption rate, and growing prevalence of multiple myeloma.

Market Scope
Base Year	2023
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	6.6%
CAGR	7.48%
Incremental Value	$2.91bn

Technavio's proteasome inhibitors market is segmented as below:

By Route Of Administration

Oral
Intravenous

By Product

VELCADE
KYPROLIS
NINLARO
Others

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the expanded application of proteasome inhibitors as one of the prime reasons driving the proteasome inhibitors market growth during the next few years. Also, special drug designation for proteasome inhibitors by regulatory agencies and high market growth potential in developing economies will lead to sizable demand in the market.

The report on the proteasome inhibitors market covers the following areas:

Proteasome inhibitors market sizing
Proteasome inhibitors market forecast
Proteasome inhibitors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading proteasome inhibitors market vendors that include Amgen Inc., Baxter International Inc., Bio Techne Corp., Bristol Myers Squibb Co., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Johnson and Johnson, Kezar Life Sciences Inc., LifeSensors Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., QLi5 Therapeutics, Takeda Pharmaceutical Co. Ltd., TG Therapeutics Inc., and Thermo Fisher Scientific Inc.. Also, the proteasome inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR73564

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global proteasome inhibitors market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global proteasome inhibitors market 2018 - 2022 ($ billion)
4.2 Route Of Administration Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Route Of Administration Segment 2018 - 2022 ($ billion)
4.3 Product Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Route of Administration

6.1 Market segments
Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%)
6.2 Comparison by Route of Administration
Exhibit 32: Chart on Comparison by Route of Administration
Exhibit 33: Data Table on Comparison by Route of Administration
6.3 Oral - Market size and forecast 2023-2028
Exhibit 34: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Oral - Year-over-year growth 2023-2028 (%)
6.4 Intravenous - Market size and forecast 2023-2028
Exhibit 38: Chart on Intravenous - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Intravenous - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Intravenous - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Intravenous - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Route of Administration
Exhibit 42: Market opportunity by Route of Administration ($ billion)
Exhibit 43: Data Table on Market opportunity by Route of Administration ($ billion)

7 Market Segmentation by Product

7.1 Market segments
Exhibit 44: Chart on Product - Market share 2023-2028 (%)
Exhibit 45: Data Table on Product - Market share 2023-2028 (%)
7.2 Comparison by Product
Exhibit 46: Chart on Comparison by Product
Exhibit 47: Data Table on Comparison by Product
7.3 VELCADE - Market size and forecast 2023-2028
Exhibit 48: Chart on VELCADE - Market size and forecast 2023-2028 ($ billion)
Exhibit 49: Data Table on VELCADE - Market size and forecast 2023-2028 ($ billion)
Exhibit 50: Chart on VELCADE - Year-over-year growth 2023-2028 (%)
Exhibit 51: Data Table on VELCADE - Year-over-year growth 2023-2028 (%)
7.4 KYPROLIS - Market size and forecast 2023-2028
Exhibit 52: Chart on KYPROLIS - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on KYPROLIS - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on KYPROLIS - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on KYPROLIS - Year-over-year growth 2023-2028 (%)
7.5 NINLARO - Market size and forecast 2023-2028
Exhibit 56: Chart on NINLARO - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on NINLARO - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on NINLARO - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on NINLARO - Year-over-year growth 2023-2028 (%)
7.6 Others - Market size and forecast 2023-2028
Exhibit 60: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Others - Year-over-year growth 2023-2028 (%)
7.7 Market opportunity by Product
Exhibit 64: Market opportunity by Product ($ billion)
Exhibit 65: Data Table on Market opportunity by Product ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Japan - Market size and forecast 2023-2028
Exhibit 91: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.9 UK - Market size and forecast 2023-2028
Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.10 Canada - Market size and forecast 2023-2028
Exhibit 99: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.11 Germany - Market size and forecast 2023-2028
Exhibit 103: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ billion)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 Amgen Inc.
Exhibit 115: Amgen Inc. - Overview
Exhibit 116: Amgen Inc. - Product / Service
Exhibit 117: Amgen Inc. - Key offerings
12.4 Baxter International Inc.
Exhibit 118: Baxter International Inc. - Overview
Exhibit 119: Baxter International Inc. - Business segments
Exhibit 120: Baxter International Inc. - Key news
Exhibit 121: Baxter International Inc. - Key offerings
Exhibit 122: Baxter International Inc. - Segment focus
12.5 Bio Techne Corp.
Exhibit 123: Bio Techne Corp. - Overview
Exhibit 124: Bio Techne Corp. - Business segments
Exhibit 125: Bio Techne Corp. - Key offerings
Exhibit 126: Bio Techne Corp. - Segment focus
12.6 Bristol Myers Squibb Co.
Exhibit 127: Bristol Myers Squibb Co. - Overview
Exhibit 128: Bristol Myers Squibb Co. - Product / Service
Exhibit 129: Bristol Myers Squibb Co. - Key news
Exhibit 130: Bristol Myers Squibb Co. - Key offerings
12.7 Fresenius SE and Co. KGaA
Exhibit 131: Fresenius SE and Co. KGaA - Overview
Exhibit 132: Fresenius SE and Co. KGaA - Business segments
Exhibit 133: Fresenius SE and Co. KGaA - Key news
Exhibit 134: Fresenius SE and Co. KGaA - Key offerings
Exhibit 135: Fresenius SE and Co. KGaA - Segment focus
12.8 Johnson and Johnson
Exhibit 136: Johnson and Johnson - Overview
Exhibit 137: Johnson and Johnson - Business segments
Exhibit 138: Johnson and Johnson - Key news
Exhibit 139: Johnson and Johnson - Key offerings
Exhibit 140: Johnson and Johnson - Segment focus
12.9 Kezar Life Sciences Inc.
Exhibit 141: Kezar Life Sciences Inc. - Overview
Exhibit 142: Kezar Life Sciences Inc. - Product / Service
Exhibit 143: Kezar Life Sciences Inc. - Key news
Exhibit 144: Kezar Life Sciences Inc. - Key offerings
12.10 LifeSensors Inc.
Exhibit 145: LifeSensors Inc. - Overview
Exhibit 146: LifeSensors Inc. - Product / Service
Exhibit 147: LifeSensors Inc. - Key offerings
12.11 Merck and Co. Inc.
Exhibit 148: Merck and Co. Inc. - Overview
Exhibit 149: Merck and Co. Inc. - Business segments
Exhibit 150: Merck and Co. Inc. - Key news
Exhibit 151: Merck and Co. Inc. - Key offerings
Exhibit 152: Merck and Co. Inc. - Segment focus
12.12 Novartis AG
Exhibit 153: Novartis AG - Overview
Exhibit 154: Novartis AG - Business segments
Exhibit 155: Novartis AG - Key offerings
Exhibit 156: Novartis AG - Segment focus
12.13 Pfizer Inc.
Exhibit 157: Pfizer Inc. - Overview
Exhibit 158: Pfizer Inc. - Product / Service
Exhibit 159: Pfizer Inc. - Key news
Exhibit 160: Pfizer Inc. - Key offerings
12.14 QLi5 Therapeutics
Exhibit 161: QLi5 Therapeutics - Overview
Exhibit 162: QLi5 Therapeutics - Product / Service
Exhibit 163: QLi5 Therapeutics - Key offerings
12.15 Takeda Pharmaceutical Co. Ltd.
Exhibit 164: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibit 165: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibit 166: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibit 167: Takeda Pharmaceutical Co. Ltd. - Key offerings
12.16 TG Therapeutics Inc.
Exhibit 168: TG Therapeutics Inc. - Overview
Exhibit 169: TG Therapeutics Inc. - Product / Service
Exhibit 170: TG Therapeutics Inc. - Key offerings
12.17 Thermo Fisher Scientific Inc.
Exhibit 171: Thermo Fisher Scientific Inc. - Overview
Exhibit 172: Thermo Fisher Scientific Inc. - Business segments
Exhibit 173: Thermo Fisher Scientific Inc. - Key news
Exhibit 174: Thermo Fisher Scientific Inc. - Key offerings
Exhibit 175: Thermo Fisher Scientific Inc. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 176: Inclusions checklist
Exhibit 177: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 178: Currency conversion rates for US$
13.4 Research methodology
Exhibit 179: Research methodology
Exhibit 180: Validation techniques employed for market sizing
Exhibit 181: Information sources
13.5 List of abbreviations
Exhibit 182: List of abbreviations